Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

O'Melveny & Myers is defending Abbott Laboratories in a pending class action against the company and two other co-defendants, ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Abbott Laboratories (ABT) stock saw a decline, ending the day at $114.88 which represents a decrease of $-3.25 or -2.75% from the prior close of $118.13. The stock opened at $117.5 and touched a low ...

The cast of 'Abbott Elementary' are being rewarded for the show's success with major salary increases heading into Season 4.

Abbott has launched its over-the-counter continuous glucose monitoring system Lingo in the U.S., days after a rival started ...

The stock's fall snapped a two-day winning streak.

Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 ...

Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.

Cardiovascular disease is rising, and Abbott Laboratories is well-positioned in the CVD treatment space. Read why I'm neutral ...